Literature DB >> 20437115

Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?

David W Dougherty1, Jonathan W Friedberg.   

Abstract

Primary treatment for classic Hodgkin lymphoma (HL) remains highly effective with chemotherapy alone or combined-modality therapy. The limitations of therapy have been related to toxicity and efficacy in subsets of patients. The introduction of a number of new and novel cytotoxic agents has provided opportunities for investigating their use in the treatment of HL. This article briefly reviews current primary treatment strategies for HL and examines the existing data for both new cytotoxic agents and other selected novel agents in the treatment of HL.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20437115     DOI： 10.1007/s11899-010-0054-x

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  40 in total

1.  High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease.

Authors:  V Bonfante; S Viviani; L Devizzi; A Di Russo; M Di Nicola; M Magni; P Matteucci; S Grisanti; P Valagussa; G Bonadonna; A M Gianni
Journal:  Eur J Haematol Suppl       Date:  2001-07

2.  Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.

Authors:  T Baetz; A Belch; S Couban; K Imrie; J Yau; R Myers; K Ding; N Paul; L Shepherd; J Iglesias; R Meyer; M Crump
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

3.  Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.

Authors:  Evert M Noordijk; Patrice Carde; Noëlle Dupouy; Anton Hagenbeek; Augustinus D G Krol; Johanna C Kluin-Nelemans; Umberto Tirelli; Mathieu Monconduit; José Thomas; Houchingue Eghbali; Berthe M P Aleman; Jacques Bosq; Marjeta Vovk; Tom A M Verschueren; Anne-Marie Pény; Théodore Girinsky; John M M Raemaekers; Michel Henry-Amar
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

4.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Lars Møller Pedersen; Thora Buhl; Jesper Jurlander; Simon Buus; Susanne Keiding; Francesco D'Amore; Anne-Marie Boesen; Anne Kiil Berthelsen; Lena Specht
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

5.  Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma.

Authors:  John Kuruvilla; Tracy Nagy; Melania Pintilie; Richard Tsang; Armand Keating; Michael Crump
Journal:  Cancer       Date:  2006-01-15       Impact factor: 6.860

6.  Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma.

Authors:  Gaetano Corazzelli; Rosaria De Filippi; Gaetana Capobianco; Ferdinando Frigeri; Vincenzo De Rosa; Giancarla Iaccarino; Filippo Russo; Manuela Arcamone; Cristina Becchimanzi; Stefania Crisci; Gianpaolo Marcacci; Barbara Amoroso; Secondo Lastoria; Antonio Pinto
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

7.  Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: a comparison with vincristine.

Authors:  H C Toh; L Sun; C H Koh; S E Aw
Journal:  Leuk Lymphoma       Date:  1998-09

8.  The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease.

Authors:  C Fermé; Y Bastion; E Lepage; F Berger; P Brice; P Morel; J Gabarre; G Nédellec; O Reman; N Chéron
Journal:  Ann Oncol       Date:  1995-07       Impact factor: 32.976

9.  Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

Authors:  Andreas Engert; Jeremy Franklin; Hans Theodor Eich; Corinne Brillant; Susanne Sehlen; Claudio Cartoni; Richard Herrmann; Michael Pfreundschuh; Markus Sieber; Hans Tesch; Astrid Franke; Peter Koch; Maike de Wit; Ursula Paulus; Dirk Hasenclever; Markus Loeffler; Rolf-Peter Müller; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544

10.  Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute.

Authors:  V T DeVita; R M Simon; S M Hubbard; R C Young; C W Berard; J H Moxley; E Frei; P P Carbone; G P Canellos
Journal:  Ann Intern Med       Date:  1980-05       Impact factor: 25.391
View more
  5 in total

Review 1.  Integrating pharmacogenetics into gemcitabine dosing--time for a change?

Authors:  Joseph Ciccolini; Cédric Mercier; Laetitia Dahan; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2011-02-08       Impact factor: 66.675

2.  Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells.

Authors:  Jing Li; Yue-Yin Pan; Ying Zhang
Journal:  Oncol Lett       Date:  2012-10-09       Impact factor: 2.967

3.  Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.

Authors:  Mahavir B Chougule; Apurva Patel; Pratik Sachdeva; Tanise Jackson; Mandip Singh
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

4.  Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines.

Authors:  Jing Li; Yue-Yin Pan; Ying Zhang
Journal:  Oncol Lett       Date:  2012-11-07       Impact factor: 2.967

5.  Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations.

Authors:  Jing Li; Shu Wang; Zeng-Feng Su; Yuan Yuan
Journal:  Contemp Oncol (Pozn)       Date:  2016-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.